| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6504030 | SANOFI AVENTIS US | Polymorphic form of clopidogrel hydrogen sulphate |
Jun, 2019
(4 years ago) | |
| US6429210 | SANOFI AVENTIS US | Polymorphic clopidogrel hydrogenesulphate form |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6429210 (Pediatric) | SANOFI AVENTIS US | Polymorphic clopidogrel hydrogenesulphate form |
Dec, 2019
(4 years ago) | |
|
US6504030 (Pediatric) | SANOFI AVENTIS US | Polymorphic form of clopidogrel hydrogen sulphate |
Dec, 2019
(4 years ago) | |
Plavix is owned by Sanofi Aventis Us.
Plavix contains Clopidogrel Bisulfate.
Plavix has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Plavix are:
- US6429210*PED
- US6504030*PED
- US6504030
- US6429210
Plavix was authorised for market use on 17 November, 1997.
Plavix is available in tablet;oral dosage forms.
The generics of Plavix are possible to be released after 10 December, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | May 06, 2014 |
| Pediatric Exclusivity(PED) | Nov 06, 2014 |
Drugs and Companies using CLOPIDOGREL BISULFATE ingredient
Market Authorisation Date: 17 November, 1997
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of PLAVIX before it's drug patent expiration?
More Information on Dosage
PLAVIX family patents
